Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROUD48
jRCTs071200011Completed
- Sponsor
- Kowa Company, Ltd.
- Start
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Trial of pemafibrate and omega-3-acid ethyl esters in dyslipidemia and hypertriglyceridemia (2 arms), sponsored by Kowa Company, Ltd. Primary endpoint: Rate of change of fasting apolipoprotein B48 from baseline to 16 weeks. Started May 2020; status: completed.
02
Drugs
pemafibrateomega-3-acid ethyl esters
03
Conditions
dyslipidemiahypertriglyceridemia
Beyond the preview
Go deeper on jRCTs071200011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs071200011.